Leerink Partners Says Exelixis (EXEL) Sell-Off on ESMO Abstracts 'Overdone'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Exelixis (EXEL) 30-day volatility at 106 compared to 60 from a month ago
September 28, 2016 12:19 PM EDTExelixis (NASDAQ: EXEL) is recently down 17% on cabozantinib and Opdivo data concerns. 30-day call option implied volatility of 106 compares to volatility of 60 from a month ago.
... MoreExelixis (EXEL) call volume and volatility spikes as shares fall 17%
September 28, 2016 11:55 AM EDTExelixis (NASDAQ: EXEL) October 14 and 16 calls are active on total call volume of 9K contracts (3K puts). October call option implied volatility is at 99, November is at 82; compared to its 52 week range of 46 to 98.
... MoreUPDATE: Exelixis (EXEL) Falls to Session Low on Cabozantinib and Opdivo Data
September 28, 2016 11:46 AM EDT(Updated - September 28, 2016 11:57 AM, 12.56 PM EDT)
Exelixis (NASDAQ: EXEL) shares dropped Wednesday, falling 20%. The decline was tied to concerns about cabozantinib and Opdivo data and a numerically lower objected response rate vs other drugs combinations in testing.
According to Bloomberg, Stifel analyst Stephen Willey said data precludes comparisons.
... More